Prothena re­vives its for­mer lead drug, aim­ing for a small­er pop­u­la­tion with more se­vere cas­es

A high-pro­file AL amy­loi­do­sis pro­gram once left for dead has got­ten new life.

Prothena is push­ing for­ward with its for­mer lead can­di­date NEOD001, now called bir­tamimab, in a Phase III study de­spite the ex­per­i­men­tal drug’s crash and burn in a Phase IIb tri­al rough­ly three years ago. The study eval­u­at­ed bir­tamimab in rare, sec­ond-line cas­es of the dis­ease, and re­searchers al­so looked at the front­line set­ting in a Phase III that had been ex­pect­ed to fail.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.